Capricor Therapeutics reports 'that teens and young men in the advanced stages of Duchenne muscular dystrophy experienced meaningful improvements in cardiac and upper limb function after a single dose of Capricor's lead investigational product, CAP-1002'
The late breaking abstract and results presented at the late breaking poster session describe the first six months of follow-up data from the randomized 12-month Phase I/II HOPE clinical trial of CAP-1002.
- Regional left ventricular (LV) function significantly differed between treatment groups following a single dose of CAP-1002, as determined by assessments of systolic thickening of LV wall segments.
- At six months, a statistically-significant increase in mean (standard deviation, or SD) change from baseline in inferior wall segments was observed with CAP-1002 (+31.2% (46.9)) compared to the usual care group (-8.8% (27.7)) (p=0.02). Six-month mean changes in anterior (+16.3 (46.5)) and lateral (+24.5 (51.2)) wall segments numerically favored CAP-1002 as compared to usual care ((-14.1 (24.9)) (p=0.11) and (-4.5 (35.0)) (p=0.24), respectively).
No comments:
Post a Comment